Viewing nowDiozartan Tablets 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Boryung Biopharma Co., Ltd.

MFDS item code 201901616 · Approved 2019.03.18 · Insurance code 670501490
Treatment of essential hypertension and heart failure, and reduction of the risk of death after myocardial infarction
This medication is used to effectively control blood pressure in patients with essential hypertension. It is also effective for patients with heart failure intolerant to ACE inhibitors, particularly those with moderate to severe conditions (NYHA class II to IV). It helps reduce the risk of death in patients with impaired left ventricular function following a myocardial infarction. Thus, this drug is used not only for the management of hypertension and alleviation of heart failure symptoms but also for improving survival rates after a myocardial infarction.
1. Essential hypertension Take with water during or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, valsartan 80 mg once daily is recommended for oral administration. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is required, the dose may be increased up to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with this medicine at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with this medicine at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with this medicine at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with this medicine at 40 mg once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg per dose twice daily. Thereafter, over several weeks, the dose may be increased according to the patient's tolerance to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine to these patients. 5. Patients with hepatic impairment: The daily dose of this medicine should preferably not exceed 80 mg in patients with mild or moderate hepatic impairment. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy have not been established in children and adolescents under 18 years of age. The safety and efficacy have not been established in children and adolescents under 18 years of age.
This drug can cause serious harm to the fetus and newborn when taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Patients with allergic reactions to this drug, severe liver dysfunction, severely impaired kidney function, women of childbearing age, and nursing mothers should not take this medication. Certain patients, such as the elderly, those with hyperkalemia, and those with mild to moderate liver dysfunction, should use this medication cautiously as there is a risk of dangerously low blood pressure; therefore, it should be started at a low dose. While taking this medication, side effects such as headache, dizziness, fatigue, dyspepsia, and cough may occur, and in rare cases, serious adverse reactions like angioedema, renal impairment, or hepatitis may happen, so any symptoms should be discussed with medical professionals immediately. If blood pressure drops sharply, there may be instances of fainting or a drop in consciousness, so if these symptoms appear, the medication should be discontinued, and appropriate treatment should be sought. This medication can increase potassium levels, so when taken with potassium-sparing diuretics or potassium supplements, blood potassium levels should be monitored closely. Interactions may occur when taken with other antihypertensives, diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), so it is crucial to inform healthcare providers or pharmacists. This medication may cause dizziness or drowsiness while driving or operating machinery, so caution is advised. It is preferable not to take this medication during pregnancy or breastfeeding, and if it must be taken, a doctor should be consulted. Safety and efficacy in children and adolescents have not been sufficiently established, so its use is not recommended. In case of overdose, severe hypotension and decreased consciousness may occur, so immediate medical attention is needed.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a well-sealed container to prevent air and moisture ingress. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain the efficacy of the medication.
Oval film-coated tablet in orange with a gray hue
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Boryung Biopharma Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.